103057-10-9

Basic information

• Product Name: 4-(CHLOROMETHYL)-1-TRITYL-1H-IMIDAZOLE
• Synonyms: 4-(CHLOROMETHYL)-1-TRITYL-1H-IMIDAZOLE;4-(chloromethyl)-1-(triphenylmethyl)-1H-Imidazole
• CAS NO: 103057-10-9
• Molecular Formula: C₂₃H₁₉ClN₂
• Molecular Weight: 358.86
• Mol File: 103057-10-9.mol

Chemical Properties

• Melting Point: 139-141 °C
• Boiling Point: 503.4°C at 760 mmHg
• Flash Point: 258.3°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 9.08E-10mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 5.28±0.70(Predicted)
• CAS DataBase Reference: 4-(CHLOROMETHYL)-1-TRITYL-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(CHLOROMETHYL)-1-TRITYL-1H-IMIDAZOLE(103057-10-9)
• EPA Substance Registry System: 4-(CHLOROMETHYL)-1-TRITYL-1H-IMIDAZOLE(103057-10-9)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 103057-10-9(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-(Chloromethyl)-1-trityl-1H-imidazole is used as a reagent for chemical synthesis processes due to its reactivity. The chloromethyl group allows for various chemical reactions, making it a versatile compound in the synthesis of other organic compounds.
Used in Laboratory Research:
4-(Chloromethyl)-1-trityl-1H-imidazole is used as a research compound in academic and industrial laboratories. Its unique structure and reactivity make it a valuable tool for studying chemical reactions and exploring new synthetic pathways.
Used in Pharmaceutical Development:
4-(Chloromethyl)-1-trityl-1H-imidazole is used as a building block in the development of new pharmaceuticals. Its reactivity and structural features can be exploited to create novel drug candidates with potential therapeutic applications.
Used in Material Science:
4-(Chloromethyl)-1-trityl-1H-imidazole is used as a component in the synthesis of new materials with specific properties. Its reactivity can be utilized to create materials with tailored characteristics for various applications, such as in electronics or advanced materials.

InChI:InChI=1/C23H19ClN2/c24-16-22-17-26(18-25-22)23(19-10-4-1-5-11-19,20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-15,17-18H,16H2

Upstream product

• 76-83-5 trityl chloride 
• 33769-07-2 4-(hydroxymethyl)-1-(triphenylmethyl)imidazole 

Downstream Products

• 122027-50-3 4-<2-phenyl-2-(4-pyridinyl)ethyl>-1-tritylimidazole 
• 122027-52-5 2-[1-Phenyl-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-pyridine 
• 397867-86-6 methyl N-benzoyl-N-[piperidin-4-yl-N-(tritylimidazol-4-ylmethyl)]-(S)-methioninate 
• 443923-67-9 4-(2-thiophen-2-yl-vinyl)-1-trityl-1H-imidazole 
• 473659-26-6 4-(4-phenyl-but-1-enyl)-1-trityl-1H-imidazole 
• 473659-27-7 4-(5-phenyl-pent-1-enyl)-1-trityl-1H-imidazole 

Relevant articles and documents

Targeting GRP receptor: Design, synthesis and preliminary biological characterization of new non-peptide antagonists of bombesin

We report the rational design, synthesis, and in vitro preliminary evaluation of a new small library of non-peptide ligands of Gastrin Releasing Peptide Receptor (GRP-R), able to antagonize its natural ligand bombesin (BN) in the nanomolar range of concen

ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE

The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

HETEROARYL RHEB INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.

Synthesis method of calmodulin inhibitor for treating brain-derived diseases

The invention discloses a synthesis method of a calmodulin inhibitor for treating brain-derived diseases and belongs to the technical field of synthesis of chemicals. The technical scheme is characterized in that a synthetic route of the synthesis method

Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I

A series of compounds based on the carboxyl-terminal CAAL sequence of PGGTase-I substrates was designed and synthesized. Using piperazin-2-one as a semi-rigid scaffold, we have introduced critical pharmacophores in a well-defined arrangement to mimic the CAAL sequence. High potency and exceptional selectivity were obtained for inhibition of PGGTase-I with structures such as 45 and 70. Potency of this series of GGTIs was dependent on the presence of an l-leucine residue with a free carboxyl terminus, as well as an S configuration of the 3-aryl group. The selectivity was significantly enhanced by 5-methyl substitution on the imidazole ring and fluorine substitution on the 3-aryl group. Modification of the 6-position of the piperazinone scaffold was found to be unfavorable. Compounds 44 and 69, the corresponding methyl esters of 45 and 70, were found to selectively block processing of Rap1A by PGGTase-I in whole cells with IC50 values of 0.4 M and 0.7 M respectively. The Royal Society of Chemistry 2006.

Design, synthesis, and pharmacological evaluation of new farnesyl protein transferase inhibitors

New CA1A2X peptidomimetics are described as Ras farnesyl transferase inhibitors (FTIs). They include cysteine and methionine as mimetics of the C-terminus sequence of farnesylated proteins. Furthermore, cysteine was replaced by heter

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent

4-METHOXY-5-METHYL-PYRAN-3-OL NATURAL PRODUCTS AND DERIVATIVES THEREOF

Novel antibiotic substances, including novel natural products, having the general formula wherein R1 and R2 are as defined herein, are disclosed. These compounds have been found to be cytochrome P450 inhibitors.

5-(HETEROCYCLYLALKANOYL)AMINO-4-HYDROXYPENTANAMIDES

This invention concerns novel nitrogen derivatives of the formula I STR1 (and their pharmaceutically-acceptable salts), together with pharmaceutical compositions containing them. The nitrogen derivatives are inhibitors of the catalytic action of renin. Th